



BioCeramic Therapeutics Elects New Chairman Dr Stephan Rietiker **Company taps global experience as it drives towards commercialisation**

London, 19 October 2009 ... Dr Stephan Rietiker MD, a recognised leader in the global medical health sector, has been appointed chairman of the board of directors of BioCeramic Therapeutics (BCT), an emerging leader in the field of novel biomaterials for healthcare.

Dr Stephan Rietiker has a proven track record in both large publicly held and privately held healthcare companies, and has considerable expertise in turning technologies into businesses. He brings a wealth of knowledge and experience from the international medical devices industry to BCT. In particular, his in-depth understanding of the challenges facing growing companies in medtech will prove invaluable as BCT enters a period of product commercialisation in 2010. He joined the board as a non-executive Director in December 2008.

Dr Stephan Rietiker has held various positions with increasing responsibility in marketing and general management with Roche, Boehringer Mannheim and Schering Plough before becoming Vice President and General Manager Europe for Covance Central Laboratory Services. He has also been President and CEO, of Sulzer Medica (later Centerpulse) and was CEO at IMI Intelligent Medical Implants. Since 2005, Dr Rietiker has been a Senior Advisor of Brown Brothers Harriman's Corporate Finance Team. Dr Rietiker also manages his own investment platform AurigaVision AG, based in Zug, Switzerland. "Over the last year BioCeramic Therapeutics has begun the exciting transition to commercialisation stage, with the Company's first products expected to be launched in 2010," said Dr Rietiker. "I am delighted to step up to the role of Chairman on the Board of BCT, a company with incredible potential to transform current practice in orthopaedics to the benefit of patients."

Sir Richard Sykes, formerly chairman and chief executive of pharmaceuticals company GlaxoSmithKline and Rector of Imperial College London, will step down as Chairman following Dr Rietiker's appointment. Sir Richard expressed his continued support for BCT as it enters its next stage of growth. The company and team wish to thank Sir Richard for his stewardship, and his time and commitment to the company. Sir Richard said, "BioCeramic Therapeutics is an exciting company with a great product pipeline, on the cusp of commercialisation." Sir Richard has retired from the board due to significant and competing workload and responsibilities.

About BioCeramic Therapeutics Limited BCT is a pioneer in the exciting new field of regenerative medicine, bringing together some of the world's best materials scientists, doctors, biologists and chemists in both private and public sectors. BCT is developing two families of implants designed to promote tissue regeneration. Initial applications are in orthopaedics and oral care, with plans to extend this to a wide range of other tissues important in human diseases. Please visit: www.bioceramictherapeutics.com.

For further information, please contact: College Hill BioCeramic Therapeutics Tony Stephenson, Benjamyn Tan, Sue Charles Daniel Green Tel: +44 (0)20 7866 7864 Tel +44 (0)20 7594 1326 E-mail: tony.stephenson@collegehill.com Email : djg@bioceramictherapeutics.com